PNT News and Press, POINT Biopharma Global Inc. From 09/06/22

Radiopharmaceutical company Point Biopharma Global Inc. ( NASDAQ: PNT ) dropped ~28% after the biotech announced the publication of an abstract containing initial data from a Phase 3 trial for its radioligand agent PNT2002. The data from the lead-in cohort of the multi-c...

Shares of the anti-cancer radiopharmaceutical company Point Biopharma Global (NASDAQ: PNT) were down by a hefty 25.1%, on sky-high volume, as of 12:10 p.m. ET Tuesday afternoon. The cancer specialist's shares are under heavy pressure today in response to an upcoming poster presentat...

INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced data will be release...

In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 18, 2022 (GLOBE NEWSWIRE...

POINT Biopharma Global press release ( NASDAQ: PNT ): Q2 GAAP EPS of -$0.27 misses by $0.05 . As of June 30, 2022, POINT had approximately $204.3 million in cash, cash equivalents and investments, which is anticipated to fund operations into the first quarter of 2024. ...

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha targeted program, enters Phase 1 clinical trial INDIANAPOLIS, Aug. 12, 2022 (GLOBE NEWSWIRE) -- POINT B...

The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at https://hub.pointbiopharma.com/controlarm INDIANAPOLIS, Aug. 08, 2022...

Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company) ...

INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that the Company’...

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy INDIANAPOLIS, May 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma G...